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Abstract
Background. Liver cirrhosis is a pathological condition that describes the end stage of liver fibrosis. Fibrosis 
is currently a two-way process. The process of returning from fibrosis now is a clinical reality. According to 
Abraldes et al. (2009), administration of simvastatin for one month will increase liver cell regeneration and 
improve endothelial dysfunction. Liver biopsy is still the gold standard for assessing liver cirrhosis, but this 
procedure is invasive and has the potential to cause life-threatening complications. Liver biopsy is complicated 
by sampling errors (reaching 30%) and different abilities between observers. Transient elastography (Fibro 
scan) is a non-invasive modality for diagnosing liver fibrosis that has high sensitivity and specificity.
Aim. The aim of the study was to discover the difference in effect, of simvastatin 20 mg compared to 10 
mg for 3 months to improve liver stiffness in patients with liver cirrhosis.
Method. The study design used a double blind, randomized clinical trial. The subjects of the study consisted 
of a group given simvastatin 10 mg / day and the group given simvastatin 20 mg / day for 3 months. Routine 
medications for cirrhosis were still made according to the original dose. During the study, an initial and 
final transient elastography examination was carried out and monthly supervision of medication compliance 
and side effects. Data analysis for statistical tests was carried out by t-test, Mann Whitney test, fisher’s-exact 
test, and ANOVA test.
Result. A total of 21 subjects underwent thorough research and transient elastography. The simvastatin 10 
mg group (n = 12) experienced a decrease in liver stiffness, with a delta mean of liver stiffness of -4.97 + 
7.09 (p <0.023) compared to the simvastatin 20 mg group (n = 9) with a heart stiffness of -4.09 + 10.06 
(p= 0.982). Changed liver stiffness in the two groups were not statistically significant differences. Etiology 
and confounding drugs showed statistically no significant effect.
Conclusion. Both simvastatin 10 mg and 20 mg can reduce liver stiffness. The effect of the two doses of 
the drug in reducing liver stiffness was not statistically significant different.
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Abstrak
Latar Belakang. Sirosis hati adalah keadaan patologis yang menggambarkan stadium akhir fibrosis hati. 
Fibrosis saat ini merupakan proses dua arah. Proses pengembalian dari fibrosis saat ini adalah suatu realitas 
klinis. Menurut penelitian Abraldes et al. (2009), pemberian simvastatin selama satu bulan akan meningkatkan 
regenerasi sel hati dan memperbaiki disfungsi endotel. Biopsi hati masih menjadi baku emas untuk menilai sirosis 
hati, akan tetapi prosedur ini invasif dan berpotensi menimbulkan komplikasi yang mengancam nyawa. Biopsi 
hati dipersulit dengan kesalahan pengambilan sampel (mencapai 30%) dan beda kemampuan antar pengamat. 
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Introduction
Liver cirrhosis is the 14th worldwide most 
common caused death in adult populations. 
Indonesia’s prevalence of liver cirrhosis in 
2007 ranged from 1-2.4%. The prevalence is 
(1.7%), it estimated that more than 7 million 
of Indonesian people have liver cirrhosis. 
Prevalence of liver cirrhosis in Dr. Sardjito 
General Hospital Yogyakarta were from 4.1% 
of patients admitted to the Internal Medicine 
Department during the 2004 period.1
Clinical symptoms of cirrhosis of the liver 
vary greatly. Compensate liver cirrhosis take 
several years to become decompensated, which 
characterized by the development of the following 
complications: jaundice, variceal bleeding, ascites 
and/or encephalopathy. Other complications 
occur mainly because of hyper dynamic portal 
and circulatory hypertension.2 Patients with 
cirrhosis also need screening for hepatocellular 
carcinoma every 6 to 12 months.3 
Parenchymal and non-parenchymal cells 
involved in the initiation and progression 
of liver fibrosis until cirrhosis.4 Liver injury 
caused necrosis and/or cell apoptosis. Release 
of cell content and reactive oxygen species 
(ROS) will activate stellate cells and attract 
and activate tissue macrophages.5 Exposure 
to inflammatory cytokines causes stellate cell 
changes to become active.6 This activation was 
a very important event in the initiation and 
progression of liver fibrosis and contributes 
greatly to collagen deposition.7
Liver biopsy is important in identifying 
fibrosis and monitoring progression of liver 
disease.8 Liver biopsy is still the gold standard 
for assessing liver cirrhosis, but this procedure 
is invasive and has the potential to cause 
life-threatening complications.9 Currently 
transient elastography is a new non-invasive 
modality to diagnose liver fibrosis due to 
various etiologies. Transient elastography 
sensitivity when compared with liver biopsy 
in stage F> 1, F>2, F> 3 and F> 4 respectively 
83.7%; 87.5%; 93.7% and 96.2% (95% 
CI). Whereas the specificities are respectively 
78.2%; 78.4%; 91.1% and 92.2% .10
Transient elastography (Fibroscan) adalah modalitas non-invasif untuk mendiagnosis fibrosis hati yang memiliki 
sensitifitas dan spesifisitas yang tinggi. 
Tujuan. Mengetahui perbedaan pengaruh simvastatin 20 mg dibandingkan 10 mg selama 3 bulan terhadap 
perbaikan kekakuan hati penderita sirosis hati.
Metode. Rancangan penelitian menggunakan uji klinis acak tersamar ganda. Subyek penelitian terdiri dari 
kelompok yang diberi simvastatin 10mg/hari dan kelompok yang diberi simvastatin 20mg/hari selama 3 
bulan. Obat-obat rutin untuk sirosis tetap diberikan sesuai dengan dosis semula. Selama penelitian dilakukan 
pemeriksaan transient elastography awal dan akhir penelitian serta pengawasan setiap bulan terhadap kepatuhan 
makan obat dan efek samping. Analisis data untuk uji statistik dilakukan dengan uji-t, uji Mann Whitney, uji 
fisher’s-exact, dan uji anova.
Hasil. Sebanyak 21 subyek menjalani penelitian dan transient elastography dengan tuntas. Kelompok simvastatin 
10 mg (n=12) mengalami penurunan kekakuan hati, dengan rerata delta kekakuan hati -4, 97 + 7, 09 (p<0,023) 
dibandingkan kelompok simvastatin 20 mg (n=9) dengan rerata delta kekakuan hati -4,09 + 10,06 (p=0,982). 
Perubahan kekakuan hati pada kedua kelompok secara statistik tidak berbeda segnifikan. Analisis etiologi dan 
obat perancu menunjukkan hasil yang secara statistik tidak berpengaruh signifikan.
Kesimpulan. Baik simvastatin 10 mg maupun 20 mg mampu menurunkan angka kekakuan hati. Pengaruh 
kedua dosis obat tersebut dalam menurunkan kekakuan hati secara statistik tidak berbeda signifikan.
Kata kunci: sirosis hati, simvastatin, fibro scan, transient elastography
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At present, anti-fibrosis drugs continue 
to be produced. According to Abraldes et al. 
(2009) research, giving simvastatin for one 
month will increase liver cell regeneration and 
improve endothelial dysfunction in hepatic 
blood vessels in patients with cirrhosis so that it 
can decrease the effectiveness rate of fibrosis to 
reduce port pressure. 11 HMG-CoA-reductase 
inhibitor (Statins) are classified in drugs that 
inhibit liver cell migration / proliferation.12
Previous research is known to compare 
simvastatin 20 mg and placebo to assess 
cirrhotic patients with transient elastography. 
No studies have been found that compare the 
effect of giving simvastatin doses of 20 mg 
and 10 mg in patients with liver cirrhosis with 
Child Pugh A and B on the results of transient 
elastography.
Method
Double-blind randomized trial was used 
to investigate the effect of simvastatin 20 mg 
and simvastatin 10 mg for 3 months to improve 
liver stiffness in patients with liver cirrhosis. 
Selection of therapy for 3 months based on 
Abraldes et al. (2009) that simvastatin therapy 
for 1 month reduced portal hypertension 
and according to Kumar et al. (2014) statin 
therapy for at least 3 months can inhibit 
decompensation in liver cirrhosis.11, 13 
The study was conducted at Dr.  Sardjito 
General Hospital Yogyakarta in 2016. The 
study subjects underwent the first transient 
elastography examination and were given 
simvastatin 20 mg compared to the group 
given simvastatin 10 mg for 3 months and 
followed by clinical development and transient 
elastography evaluation.
Patients with liver cirrhosis were the 
target population of the study, while the 
affordable populations were adult patients 
who met the inclusion and exclusion criteria. 
There were two inclusion criteria. First, were 
patients who had erected child Pugh A & B 
cirrhosis based on clinical, laboratory, and 
liver ultrasonography, aged over 18 years who 
were treated at the gastroentero Hepatology 
polyclinic of Dr. Sardjito General Hospital 
Yogyakarta. Second, were agreed to participate 
in research by signing the consent sheet. 
There were five exclusion criteria of the 
study. The first was subject with alcoholic 
fatty liver. The second were subjects with 
liver cirrhosis that progress to hepatocellular 
carcinoma (KHS). Third were subjects with 
liver cirrhosis with comorbid sepsis, chronic 
renal failure, chronic heart failure, acute 
stroke, acute complications diabetes mellitus 
(DM) namely diabetic ketoacidosis (KAD), 
coma hyperosmolar hyperglycemia and 
hypoglycemia and malignancies in addition 
to the liver. Fourth were subjects with liver 
cirrhosis who had experienced complications 
of hepatorenal syndrome and acute liver 
failure. Fifth, where subjects with obtaining 
simvastatin therapy before the study and the 
last were subjects with ascites and/or obesity.
The subjects were randomly divided 
into two groups. The first group had given 
simvastatin 20mg/day and the second group 
was given simvastatin 10mg/day, both treated 
in 3 months. Routine medications for cirrhosis 
were still given according to the original dosage. 
The subjects of the study were completed 
examination of history, physical examination, 
and laboratory examination. Then performed 
an ultrasound examination and transient 
elastography at the beginning and at the end 
of treatment.
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Result 
The study running for 6 months, from 
January to June 2018. The number of cases 
with liver cirrhosis who underwent outpatient 
care at the Gastroentero Hepatology clinic 
in Dr. Sardjito General Hospital and contact 
with researchers as many as 57 subjects. 
Subjects who met the inclusion criteria for 
the study were 51 subjects, but 9 subjects 
were excluded from 3 subjects because they 
received simvastatin therapy within the 
previous 2 months, 1 subjects were diagnosed 
with HCC (Hepatocellular carcinoma) and 
5 subjects were not willing to take the study. 
Here the result was 42 subjects willing to 
conduct the study.
The study started with computerized 
sys tem and inter v iew,  a l so  phys ica l 
examinations, and laboratory tests. Both 
groups were given simvastatin 10 mg or 20 
mg for 3 months. Researcher and subjects were 
not aware of the intervention given because 
simvastatin 20 mg and 10 mg were given to the 
subjects used capsules of the same shape and 
color. A total of 42 research subjects underwent 
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Figure 1. Flow of research 
 
 
57 subjects with liver cirrhosis control at the Gastroentero hepatology polyclinic 
Dr. Sardjito Hospital on January-March 2018 
Meet the inclusion criteria of 51 subjects 
Excluded 4 subjects 
47 subjects met the study criteria 
42 subjects were willing to take part in the study 
 
5 subjects were not willing to take part in the 
study 
Simvastatin 10 mg (n= 21) Simvastatin 20 mg (n= 21) 
Simvastatin 10 mg 
(n= 12) 
4 subjects did not complete the study: 
• 1 subject diagnosed with MDS (month 1) 
• 1 subject died (month 1) 
• 1 subject move right to treatment (month 3) 
• 1 subject was not in control (end of month 3) 
8 subjects did not meet fibro scan 
requirements: 
• 1 obese subject 
• 2 subjects with liver shrinkage 
• 5 ascites subjects Simvastatin 20 mg 
(n= 9) 
9 subjects did not meet fibro scan 
requirements: 
• 2 obese subjects 
• 2 subjects with liver shrinkage 
• 5 ascites subjects 
Randomization 
Figure 1. Flow of research
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continued until the end of the study. A total 12 
subjects in the simvastatin 10 mg group, and 
the simvastatin 20 mg group were 9 subjects 
for further analysis of the data.
The basic characteristics of the study 
subjects were difference changed in liver 
stiffness in subjects with liver cirrhosis treated 
with simvastatin 20 mg compared with 10 mg 
described in table 1.
There were 21 research subjects divided 
into two treatment groups. The simvastatin 
10 mg group consisted of 12 subjects and 
the simvastatin 20 mg group as many as 9 
subjects. In both groups, the average age in 
the simvastatin 10 mg group was 56 years 
while in the simvastatin group 20 mg was 60 
years. The gender in the simvastatin 10 mg 
group was mostly male at 83.3% and in the 
simvastatin group 20 mg the majority were 
Table 1. Basic Characteristics of Research Subjects
Characteristics
Simvastatin 10mg Simvastatin 20mg
pn 
(12) %




Mean ± SD/Median 
(min-max)
Age 56.17±6.25 60.78± 9.02 0.182a
Gender
Male 10 83.3% 3 33.3% 0.032b
Female 2 16.7% 6 66.7%
Education
Uneducated 1 8.3% 0 0.0%
0.744c
Elementary School 3 25.0% 1 11.1%
Junior High School 2 16.7% 2 22.2%
Senior High School 4 33.3% 3 33.3%
Diploma/Bachelor 2 16.7% 3 33.3%
Occupation
Housewife 0 0.0% 4 44.4% 0.095c
Civil servants 2 16.7% 1 11.1%
Retired 1 8.3% 2 22.2%
Private employees 1 8.3% 1 11.1%
Entrepreneur 3 25.0% 0 0.0%
Farmer 2 16.7% 1 11.1%
Freelancer 3 25.0% 0 0.0%
Etiology
Hepatitis B 10 83.3% 6 66.7% 0.128c
Hepatitis C 0 0.0% 1 11.1%
NAFLD 0 0.0% 2 22.2%
Others  2 16.7% 9 0.0%
Propranolol
Yes 12 100% 9 100% -
No 0 0.0% 0 0.0%
Spironolactone
Yes 10 83.3% 9 100% 0.486b
No 2 16.7% 0 0.0%
Vitamin K
Yes 3 25.0% 9 33.3% 1.000 b
No 9 75.0% 6 66.7%
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female as much as 66.7%. The education level 
of the research subjects in the simvastatin 10 
mg group included Senior High School at 
33.3%, Elementary School 25%, Junior High 
School 16.7%, Diploma / Bachelor 16.7%, 
while in the Simvastatin group 20 mg the level 
of education included Diploma or Bachelor 
33.3 %, Senior High School 33.3%, Junior 
High School 22.2% and Elementary School 
11.1%. Liver cirrhosis in the two majority 
groups were caused by Hepatitis B where in 
the simvastatin 10 mg group was 83.3% and 
in the Simvastatin 20 mg group was 66.7%. 
For routine medication in both groups used 
propranolol at 100%, in the simvastatin 
10 mg group was 83.3% of patients used 
Characteristics
Simvastatin 10mg Simvastatin 20mg
pn 
(12) %




Mean ± SD/Median 
(min-max)
Lamivudine
Yes 4 33.3% 4 44.4% 0.673 b
No 8 66.7% 5 55.6%
Telbivudine
Yes 3 25.0% 1 11.1% 0.603 b
No 9 75.0% 8 88.9%
Tenofovir
Yes 1 8.3% 0 0.0% 1.000 b
No 11 91.7% 9 100%
Sofosbuvir
Yes 0 0.0% 0 0.0% -
No 12 100% 9 100%
Daclatasvir
Yes 0 0.0% 0 0.0% -
No 12 100% 9 100%
Smoking
Yes 8 66.7% 1 11.1% 0.024 b
No 4 33.3% 8 88.9%
Nutritional Status
Obesities 0 0.0% 0 0.0% 0.142c
Overweight 0 0.0% 1 11.1%
Normal 1 8.3% 3 33.3%
Underweight 11 91.7% 5 55.6%
Early Child Pugh
A 11 91.7% 8 88.9% 1.000b
B 1 8.3% 1 11.1%
BMI 23.33±2.23 23.74±4.05 0.769a
Hb 11.27±3.33 12.13±1.71 0.486a
Early BUN 11.9(5.0-71.0) 11.5(8.0-20.3) 0.749d
Early CREA 1.05±21 0.99±.21 0.575a
Early CCT 68.07±16.97 58.05±15.79 0.184a
Early INR 1.34±.19 1.28±.14 0.394a
Early TBIL 1.11±.51 1.30±.38 0.370a
Early Alb 3.89±.57 3.68±.62 0.422a
Early MELD 11.25±2.22 10.89±1.83 0.696a




spironolactone, while in the simvastatin group 
20 mg was 100%. The used of vitamin K in 
the simvastatin 10 mg group was 25% and 
in the simvastatin 20 mg group was 33.3%. 
More used of antiviral drugs was found in the 
simvastatin 10 mg group, namely lamivudine, 
telbivudine, tenofovir, sofosbuvir, daclatasvir 
respectively 33.3%, 25%, 8.3%, while in the 
simvastatin 20 mg group respectively 44%, 
11%, 0%. In both groups did not used of 
sofosbuvir and daclatasvir was obtained. 
The nutritional status of the two groups 
were approximately the same as the average body 
mass index is 23.3 kg/m2 and 23.7 kg/m2. Child 
Pugh in the two majority groups was Child Pugh 
A, the Simvastatin 10 mg group was 91.7% and 
the Simvastatin 20 mg group was 88.9%. Overall, 
the characteristics of the sample are almost similar, 
except for gender and smoking habits. Both 
variables indicate a significant difference. In the 
simvastatin 10 mg group the number of men 
and women, respectively was 83.3% and 16.7%, 
while in the simvastatin 20 mg group the number 
of men and women respectively was 33.3% and 
66.7% with p value 0.032. Smoking habits in the 
simvastatin 10 mg group were 66.7%, while in 
the simvastatin 20 mg group only 11.1% with 
p value 0.024.
In the simvastatin 10 mg group, the 
middle value of liver stiffness at the beginning 
of the study was 18.75 kPa, down to 15.45 
kPa at the end of the study with p value 0.023, 
while simvastatin 20 mg at midpoint at 26.30 
kPa dropped to 21.30 kPa with p-value 0.1.
Based on the table 2, changed liver 
stiffness in the simvastatin 10 mg group was 
statistically significant while in the simvastatin 
20 mg group was not statistically significant. 
When we compared changes in liver stiffness 
between the simvastatin 10 mg group and 
the simvastatin 20 mg group, it did not differ 
statistically significant, this change can be seen 
in table 3 with p value of 0.982.





Group Simvastatin 10mg -4.97 7.09
0.982a
Simvastatin 20mg -4.89 10.06
a = Independent T-Test (significance p<0.05)
After received simvastatin therapy for 
12 weeks, an evaluation of the occurrence of 
side effects obtained from the history, physical 
examination, and investigation (Table 4).
In this study we obtained data on the side 
effects of used simvastatin in each treatment 
group. In the Simvastatin 10 mg group there 
were 5 out of 12 subjects (41.6%) experiencing 
side effects, whereas in the simvastatin 20 mg 
group 6 of 9 subjects (66.6%) experienced 
simvastatin side effects. It appears that in 
simvastatin 20 mg, the incidence of side effects 
was higher compared to simvastatin 10 mg 
(Table 4), but statistically the two groups were 
not significantly different.
Table 2. Early and Final Differences in Liver Stiffness.
Group
Liver Stiffness Liver Stiffness
p
Median Minimum Maximum Median Minimum Maximum
Simvastatin 10mg 18.75 6.10 75.00 15.45 7.30 54.20 0.023a
Simvastatin 20mg 26.30 11.90 53.50 21.30 8.30 63.90 0.173a
a = Mann Whitney Test (significance p<0.05)
Acta Interna The Journal of Internal Medicine, Volume 10, Number 1, June 2020: 10-21
17 
In this study the etiology of liver cirrhosis 
in both groups included Hepatitis B, hepatitis 
C, non-alcoholic fatty liver disease (NAFLD) 
and other unknown causes. Further analysis was 
carried out to see the etiological relationship of 
fibrosis with liver stiffness in the two treatment 
groups.
In table 5 it appears that changes in liver 
stiffness in patients with hepatitis B were not 
significantly different from non-hepatitis B 
patients, changes in liver stiffness in patients 
with hepatitis C did not differ significantly 
from non-hepatitis C patients and changes in 
liver stiffness in NAFLD were not significantly 
different from non-patients NAFLD.
The basic characteristics that showed 
significant differences were gender and 
smoking. After analysis in table 7, both 
men and women did not show a significant 
difference in liver stiffness decreased. Likewise, 
smoking habits in both treatment groups did 
not differ significantly.
Discussion  
Liver fibrosis was a reversible wound 
healing response. The process of reaching the 
final stage of cirrhosis taken 20 to 40 years in 
patients with chronic liver injury the rate of 
development was influenced by both genetic 
and environmental factors.14
Based on research by Marron et al. 
(2014), in the liver there was a Kruppel-
like factor 2-transcription factor (KLF2) 
increased in number during the progression 
of cirrhosis to reduce the development of 






Hepatitis B Yes -4.87 7.62 0.947a
No -5.16 11.09
Hepatitis C Yes -5.70 - 0.927 a
No -4.90 8.47
NAFLD Yes 2.00 11.88 0.220 a
No -5.67 7.87
Others Yes -12.05 12.37 0.208 a
No -4.19 7.81
a = Independent T-Test (significance p<0.05), (-) = cannot 
be analyzed.
Table 6. Analysis of Routine Drugs as 
Confounding




Propanol Yes -4.93 8.25 -
No 0 0
Spironolactone Yes -4.90 8.62 0.556a
No -5.30 4.94
Vitamin K Yes -11.70 9.56 0095 a
No -2.23 6.09
Antivirus Yes -3.78 7.83 0.677 a
No -6.81 9.10
A = Independent T-Test (significance p<0.05), (-) = cannot 
be analyzed.






n= 12 % n=9 %
Sleep disorder 1 8.3 0 0 1.000a
Pruritus 0 0.0 3 33.3 0.063 a
Myalgia 1 8.3 1 11.1 1.000 a
Arthralgia 0 0.0 1 11.1 0.429 a
Paresthesia 1 8.3 2 22.2 0.553 a
Headache 1 8.3 0 0.0 1.000 a
Dizziness 0 0.0 1 11.1 0.429 a
Atypical chest pain 1 8.3 0 0.0 1.000 a
Abdominal pain 1 8.3 0 0.0 1.000 a
Nausea 0 0.0 3 33.3 0.063 a
Constipation 0 0.0 0 0.0 -
AST >3x upper limit 0 0.0 1 11.1 0.429 a
ALT >3x upper limit 0 0.0 0 0.0 -
CK >3x upper limit 0 0.0 0 0.0 -




vascular dysfunction. An in vivo study showed 
that increased regulation of KLF2 could affect 
the liver cell phenotype and could improve 
liver fibrosis, endothelial dysfunction, and 
port hypertension in cirrhosis. In the study 
simvastatin was known to induce expression of 
KLF 2 when stellate cells were active.15
Abraldes’ research in 2009 showed that 
giving simvastatin 20-40 mg for one month 
would improve liver cell regeneration and 
improve vascular endothelial dysfunction. A 
study of the administration of simvastatin 20 
mg for 4 weeks to liver stiffness scores was 
carried out in Solo, Indonesia. In this study, 
there was a significant decrease in liver stiffness 
scores with a p value equal to 0.049.16
Whereas in this study showed an 
improvement in liver stiffness scores that were 
statistically significant with the treatment of 
simvastatin for 3 months at lower doses of 
10 mg, p value = 0.023. Even so, if changes 
in liver stiffness compared between the 
two treatment groups results showed not 
significantly different.
Some conditions that affect the results 
of transient elastography include obesity, 
old age, ascites, and metabolic syndrome.17 
A total of 17 subjects were excluded due to 
obesity, ascites, and liver shrinkage. Liver 
stiffness could be affected by, among others: 
fasting status, increased transaminases, cardiac 
congestion, and extra hepatic cholestasis. The 
type and position of the probe and operator 
experience also influence the results of transient 
elastography.18
The significant difference between the 
two groups was probably due to differences in 
the number of samples where in the simvastatin 
10 mg group the number of samples was 
greater than the simvastatin 20 mg group. The 
sample in the study may not be too large or 
too small because both have limitations that 
could influence the conclusions of the study. 
Samples that were too small and less able to 
predict a possibility.19
Some other things that caused different 
results included etiology and routine medications 
used by the research subjects. Patients with liver 
cholestasis, such as primary biliary cirrhosis 
and primary sclerotic cholangitis, appear 
to be had a higher liver stiffness than viral 
hepatitis. Some conditions that could lead 
to overestimation of liver fibrosis in transient 
elastography include: increased transaminases, 
extra hepatic cholestasis and congestion of 
the heart, non-fasting conditions and liver 
steatosis.18 Liver stiffness seen with transient 
elastography in patients with chronic hepatitis 
B was similar to patients with hepatitis C at 
the same stage of fibrosis. Liver stiffness were 
also related to the severity of fibrosis in both 
hepatitis B and hepatitis C patients.20
In this study, after analysis of confounding 
factors for etiology and routine drugs used did 
not show a significant difference between the 
two treatment groups. Not only liver stiffness 
has the different results, but the frequency of 
simvastatin side effects in both groups also 
showed some differences even though it was 
not statistically significant.
Table 7. Gender and Smoking Analysis as a 
Screw




Gender Male -2.55 6.23 0.092 a
Female -8.81 10.01 0.142 a
Smoking Yes -4.24 5.65
0.748 a
No -5.45 9.99
a = Independent T-Test (significance p<0.05)
Acta Interna The Journal of Internal Medicine, Volume 10, Number 1, June 2020: 10-21
19 
The results of this study showed that 
the simvastatin 20 mg group has a greater 
frequency of side effects than in the simvastatin 
10 mg group. This could be appeared because 
of the simvastatin 20 mg group was older 
with an average age of 60 years while in the 
simvastatin 10 mg group the average age of 
the subject is 56 years. A study conducted by 
the 2008 National Institute of Health in the 
United States mentioned several risk factors for 
undesirable events due to statins, one of which 
was elderly subjects.
A study with research subjects received 
simvastatin 80 mg with basic characteristics > 
65 years of age was associated with an increased 
incidence of both definite myopathy and 
insipient myopathy with a relative risk of 2.2 
(95% CI 1.4-3.4) and 2, 3 (95% CI 1.3-4.1). 
Among patients who received simvastatin 20-
40 mg every day, the incidence of myopathy 
was typically around 1/10.000 patients/year. 
Old age also signifies fragility of mitochondria 
because DNA mutations occur with age.21
Evidence regarding matters affecting 
simvastatin side effects continues to develop 
towards the role of systemic factors were 
genetics, food intake, and estrogen use and 
bone density. Here, the mechanical factors, 
namely muscle weakness, obesity, and joint 
weakness.21.22 Various other variables were 
overall health status, comorbidity, exercise 
habits, smoking, depression, poor personal 
mastery and low education. Apart from the 
presence of risk factors, an increase in the 
incidence of simvastatin side effects was also 
influenced by drug interactions.23
In this study, the subjects involved had 
routine medications, including propranolol, 
spironolactone, vitamin K and antivirals 
(lamivudine, telbivudine and tenofovir). 
Setoguchi et al. (2010) found no synergistic 
effect between the used of propranolol and 
statins in cases of myopathy. Chronic infection 
or inflammatory conditions such as cirrhosis 
of the liver were known to have increased 
CRP levels.24 The used of beta blockers 
(metoprolol or propranolol) together with 
statins can significantly weaken the anti-
inflammatory effect.25 Statin interactions were 
also found in the used of spironolactone, where 
spironolactone could increase the level or effect 
of statins and increased the risk of muscle 
toxicity.26 While the influence of statins on oral 
vitamin K has not been widely studied.
Studied of the side effects of statins have 
shown that increased creatinine kinase and 
liver enzymes were in line with increased statin 
doses and intensity of use. Most side effects of 
statins were dose dependent in some literature 
suggested “the lower the better”. The FDA of 
United States that all statins should be given 
the lowest dose.23
Results from measurements of liver 
stiffness in 21 subjects divided into the 
simvastatin 10 mg group and simvastatin 20 mg 
showed a decrease in liver stiffness in 3 months 
of treatment. However, the decreased in liver 
stiffness that occurred in both treatment groups 
was not statistically significantly different. The 
used of simvastatin in chronic liver disease was 
a long-term used for a lifetime. In the results 
of this study and the financial considerations 
and FDA recommendations, simvastatin 10 
mg could be a good therapeutic choice. 
Conclusion
Both simvastatin 10 mg and 20 mg could 
reduce liver stiffness in patients with cirrhosis. 
The effect of the two doses of the drug in 
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